T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis

Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
Cancer Research (Impact Factor: 9.28). 05/2012; 72(9):2162-71. DOI: 10.1158/0008-5472.CAN-11-3687
Source: PubMed

ABSTRACT T-regulatory cells (Tregs) are found infiltrating tumors in a vast array of tumor types, and tumor-infiltrating Tregs are often associated with a poor clinical outcome. Tregs are potent immunosuppressive cells of the immune system that promote progression of cancer through their ability to limit antitumor immunity and promote angiogenesis. Here, we discuss the ways in which Tregs suppress the antitumor immune response and elaborate on our recent discovery that Tregs make significant direct contributions to tumor angiogenesis. Further, we highlight several current therapies aimed at eliminating Tregs in cancer patients. Given the multifaceted role of Tregs in cancer, a greater understanding of their functions will ultimately strengthen future therapies.

Download full-text


Available from: Andrea Facciabene, Oct 27, 2014
1 Follower
  • Source
    • "We found that administration of GA-A significantly suppressed metastasis of EL4 lymphoma cells to the liver, which correlated with improved survival. While Tregs are often associated with a poor clinical outcome [Facciabene et al., 2012], this study did not find any significant changes in Treg cells in vehicle versus GA-A treated mice. By contrast, we have found GA-A treatment attenuates EL4 tumor growth and metastasis by a marked inhibition of MDSC populations in the host, which could be regulated via the STAT3 pathway [Kujawski et al., 2008]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Lymphoma is a potentially life threatening disease. The goal of this study was to investigate the therapeutic potential of a natural triterpenoid, Ganoderic acid A (GA-A) in controlling lymphoma growth both in vitro and in vivo. Here, we show that GA-A treatment induces caspase-dependent apoptotic cell death characterized by a dose-dependent increase in active caspases 9 and 3, up-regulation of pro-apoptotic BIM and BAX proteins, and a subsequent loss of mitochondrial membrane potential with release of cytochrome c. In addition to GA-A's anti-growth activity, we show that lower doses of GA-A enhance HLA class II-mediated antigen presentation and CD4+ T cell recognition of lymphoma in vitro. The therapeutic relevance of GA-A treatment was also tested in vivo using the EL4 syngeneic mouse model of metastatic lymphoma. GA-A-treatment significantly prolonged survival of EL4 challenged mice and decreased tumor metastasis to the liver, an outcome accompanied by a marked down-regulation of STAT3 phosphorylation, reduction myeloid-derived suppressor cells (MDSCs), and enhancement of cytotoxic CD8+ T cells in the host. Thus, GA-A not only selectively induces apoptosis in lymphoma cells, but also enhances cell-mediated immune responses by attenuating MDSCs, and elevating Ag presentation and T cell recognition. The demonstrated therapeutic benefit indicates that GA-A is a candidate for future drug design for the treatment of lymphoma. J. Cell. Biochem. © 2014 Wiley Periodicals, Inc.
    Journal of Cellular Biochemistry 01/2015; 116(1). DOI:10.1002/jcb.24946 · 3.37 Impact Factor
  • Source
    Transplantation 01/2012; 94(10S):1014. DOI:10.1097/00007890-201211271-02006 · 3.78 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Many anticancer agents currently used are considered to be cytotoxic not only to cancer cells but also to functional immune cells. To learn more about the immunosuppressive adverse influence of chemotherapeutic drugs in cancer chemotherapy, we examined the effects of arsenic trioxide, dacarbazine, 5-fluorouracil, and methotrexate on the survival, proliferation, cytokine production, and CD4(+)CD25(+)Foxp3(+) regulatory T (Treg) cell-frequency in human peripheral blood mononuclear cells (PBMCs) activated by T cell mitogen in vitro. Arsenic trioxide, dacarbazine, and 5-fluorouracil increased trypan-blue stained (dead) cell rates and suppressed the mitogen-activated proliferation of PBMCs significantly at 1-100μM (p<0.05). Methotrexate also significantly increased the percentages of dead cells and suppressed the mitogen-activated PBMC-proliferation at concentrations of more than 0.05μM (p<0.01). Arsenic trioxide significantly inhibited the production of interferon γ, interleukin (IL)-4, -6, and -10 from the activated PBMCs at 5μM (p<0.05). In contrast, the anticancer agents significantly increased Treg cell-frequency in the activated PBMCs at concentrations of more than 0.1μM for methotrexate, 5μM for arsenic trioxide and 5-fluorouracil, and 50μM for dacarbazine, respectively (p<0.05). These agents did not significantly influence the production of transforming growth factor (TGF) β from the activated PBMCs at a concentration range of 0.05-50μM. Our data suggest that the anticancer agents: arsenic trioxide, dacarbazine, 5-fluorouracil, and methotrexate attenuate T cell mediated immunity by not only inhibiting the proliferative response of T cells but by also increasing the frequency of Treg cells, which may result in the suppression of the effector T cell function.
    International immunopharmacology 11/2012; 15(1). DOI:10.1016/j.intimp.2012.11.008 · 2.71 Impact Factor
Show more